drugset
Drugs / TGFBR2 KO CAR27/IL-15 NK cells
last change May 2026 re-read 3 minutes ago

TGFBR2 KO CAR27/IL-15 NK cells

Cell therapy targets TGFBR2 via inhibition

Developed for
malignant pancreatic neoplasm
Investigated by
M.D. Anderson Cancer Center · United States Department of Defense

Trials 1

today NCT07377526 · Ph 1/2
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT07377526 May 2026 → Mar 2028 expected malignant pancreatic neoplasm M.D. Anderson Cancer Center Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TGFBR2 KO CAR27/IL-15 NK cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07377526 ↗
Action Inhibit “TGFBR2 KO” NCT07377526 ↗
Modality Cell therapy “NK cells” NCT07377526 ↗
Route Intravenous “administered intraperitoneally and intravenously” NCT07377526 ↗
Target TGFBR2 “TGFBR2 KO” NCT07377526 ↗